PL3010910T3 - Związki pirymidynodionu przeciwko chorobom serca - Google Patents

Związki pirymidynodionu przeciwko chorobom serca

Info

Publication number
PL3010910T3
PL3010910T3 PL14738986T PL14738986T PL3010910T3 PL 3010910 T3 PL3010910 T3 PL 3010910T3 PL 14738986 T PL14738986 T PL 14738986T PL 14738986 T PL14738986 T PL 14738986T PL 3010910 T3 PL3010910 T3 PL 3010910T3
Authority
PL
Poland
Prior art keywords
pyrimidinodione
heart diseases
compounds against
against heart
compounds
Prior art date
Application number
PL14738986T
Other languages
English (en)
Inventor
Johan Oslob
Robert Anderson
Danielle Aubele
Marc EVANCHIK
Jonathan Charles FOX
Brian Kane
Puping LU
Robert Mcdowell
Hector Rodriguez
Yonghong Song
Arvinder Sran
Original Assignee
MyoKardia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3010910(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MyoKardia, Inc. filed Critical MyoKardia, Inc.
Publication of PL3010910T3 publication Critical patent/PL3010910T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL14738986T 2013-06-21 2014-06-19 Związki pirymidynodionu przeciwko chorobom serca PL3010910T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838088P 2013-06-21 2013-06-21
US201461939655P 2014-02-13 2014-02-13
US201461981366P 2014-04-18 2014-04-18
EP14738986.0A EP3010910B1 (en) 2013-06-21 2014-06-19 Pyrimidinedione compounds against cardiac conditions
PCT/US2014/043192 WO2014205223A1 (en) 2013-06-21 2014-06-19 Pyrimidinedione compounds against cardiac conditions

Publications (1)

Publication Number Publication Date
PL3010910T3 true PL3010910T3 (pl) 2020-07-27

Family

ID=51177189

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14738986T PL3010910T3 (pl) 2013-06-21 2014-06-19 Związki pirymidynodionu przeciwko chorobom serca

Country Status (39)

Country Link
US (9) US9181200B2 (pl)
EP (2) EP3010910B1 (pl)
JP (5) JP6603213B2 (pl)
KR (4) KR20220020410A (pl)
CN (2) CN105473576B (pl)
AU (5) AU2014281408B2 (pl)
BR (1) BR112015031864B1 (pl)
CA (1) CA2915967C (pl)
CL (1) CL2015003689A1 (pl)
CR (1) CR20160032A (pl)
CY (2) CY1122964T1 (pl)
DK (1) DK3010910T3 (pl)
DO (1) DOP2015000300A (pl)
EA (2) EA201891009A1 (pl)
ES (1) ES2773250T3 (pl)
FI (1) FIC20230036I1 (pl)
FR (1) FR23C1047I2 (pl)
GT (1) GT201500348A (pl)
HR (1) HRP20200379T1 (pl)
HU (2) HUE047566T2 (pl)
IL (7) IL302299A (pl)
LT (2) LT3010910T (pl)
LU (1) LUC00324I2 (pl)
MX (3) MX382520B (pl)
MY (1) MY190860A (pl)
NL (1) NL301253I2 (pl)
NO (1) NO2023043I1 (pl)
PE (1) PE20160208A1 (pl)
PH (2) PH12021552715A1 (pl)
PL (1) PL3010910T3 (pl)
PT (1) PT3010910T (pl)
RS (1) RS59906B1 (pl)
SG (2) SG10201803459TA (pl)
SI (1) SI3010910T1 (pl)
SM (1) SMT202000071T1 (pl)
TN (1) TN2015000553A1 (pl)
UA (1) UA117929C2 (pl)
WO (1) WO2014205223A1 (pl)
ZA (1) ZA201508959B (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349578B2 (en) 2010-12-23 2016-06-30 Twelve, Inc. System for mitral valve repair and replacement
CN107496054B (zh) 2011-06-21 2020-03-03 托尔福公司 人工心脏瓣膜装置及相关系统和方法
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
EP3943047B1 (en) 2011-10-19 2023-08-30 Twelve, Inc. Device for heart valve replacement
WO2013059747A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN106432222A (zh) * 2016-09-19 2017-02-22 丹诺医药(苏州）有限公司 8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
KR20250116181A (ko) * 2017-08-04 2025-07-31 미요카디아, 인크. 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐
MD3740481T3 (ro) 2018-01-19 2025-06-30 Cytokinetics Inc Analogi de dihidrobenzofuran și inden în calitate de inhibitori ai sarcomerului cardiac
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3110237A1 (en) 2018-08-31 2020-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors
SI3873904T1 (sl) * 2018-10-29 2024-10-30 MyoKardia, Inc. S tetrahidropiranom (thp) substituirane biciklične pirimidindionske spojine
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
WO2021092598A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
US20230057197A1 (en) 2020-01-28 2023-02-23 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
JP2023550444A (ja) * 2020-11-20 2023-12-01 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
CN116507621B (zh) * 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) * 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
MX2023008810A (es) * 2021-02-01 2023-08-04 Dr Reddys Laboratories Ltd Proceso de preparacion de mavacamten y formas en estado solido del mismo.
CA3209693A1 (en) * 2021-02-25 2022-09-01 Xiaobing Yan Substituted pyridine-2,4-dione derivatives
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
MX2023010673A (es) * 2021-03-17 2023-09-22 Hansoh Bio Llc Cetonas heterociclicas que contienen nitrogeno, metodos de preparacion y usos medicinales de las mismas.
JP7802077B2 (ja) * 2021-07-13 2026-01-19 日本曹達株式会社 ウラシル化合物の製造方法
JP7315632B2 (ja) * 2021-09-16 2023-07-26 楽天グループ株式会社 特典付与システム、特典付与方法、及びプログラム
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
CN118591527A (zh) * 2022-01-27 2024-09-03 深圳市康哲生物科技有限公司 7-氮杂螺[4,5]癸烷-6,10-二酮类化合物的晶型及其制备方法
CA3248508A1 (en) 2022-04-13 2023-10-19 Assia Chemical Industries Ltd. SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
CN120549937A (zh) * 2022-04-26 2025-08-29 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
US20250326743A1 (en) * 2022-05-20 2025-10-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal forms of triazine dione derivative and preparation method therefor
TW202416997A (zh) * 2022-09-16 2024-05-01 大陸商江蘇豪森藥業集團有限公司 一種含氮雜環酮化合物的晶型及其製備方法
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
CN121194963A (zh) 2023-03-27 2025-12-23 艾知怀斯治疗学公司 喹啉酮酰胺类化合物及其用途
WO2024218783A1 (en) * 2023-04-17 2024-10-24 Dasha Pharmaceuticals Private Limited Green chemistry approach for synthesis of mavacamten and its intermediate using novel methodology
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels
WO2025130408A1 (zh) * 2023-12-20 2025-06-26 福石生物科技(合肥)有限公司 一种肌球蛋白抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280877B (de) 1960-11-16 1968-10-24 Robugen Gmbh Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja) 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
JPH0637479B2 (ja) * 1987-12-28 1994-05-18 三井東圧化学株式会社 新規ピリミジン誘導体、その製造法およびそれを含有する抗不整脈剤
US5008267A (en) * 1988-10-29 1991-04-16 Mitsui Toatsu Chemicals, Incorporated Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH03173885A (ja) 1989-12-01 1991-07-29 Mitsui Toatsu Chem Inc ピリミジンジオン誘導体化合物、該化合物の製造法および該化合物を含む抗不整脈剤
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH0413669A (ja) * 1990-04-27 1992-01-17 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
JPH06128238A (ja) 1992-10-20 1994-05-10 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体
DE69500377T2 (de) 1994-08-19 1997-10-09 Mitsui Toatsu Chemicals Pyrimidin-Dion-Derivate und diese enthaltende antiarrhythmische Zusammensetzungen
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
EP0967209B1 (de) 1998-06-26 2003-01-08 Crompton Vinyl Additives GmbH Neue NH2-modifizierte 6-Aminouracile als Stabilisatoren für halogenhaltige Polymere
US7416856B2 (en) 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2001029010A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
WO2002102769A2 (en) 2001-06-15 2002-12-27 University Of Massachusetts Methods for synthesizing substituted pyrimidines
US20030114414A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi Methods for synthesizing substituted pyrimidines
US20030114445A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
DE10208460A1 (de) 2002-02-27 2003-09-04 Bayer Ag Uracil-Thioether
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds

Also Published As

Publication number Publication date
CL2015003689A1 (es) 2016-10-14
US20230165860A1 (en) 2023-06-01
RS59906B1 (sr) 2020-03-31
FR23C1047I2 (fr) 2024-11-15
EP3010910B1 (en) 2020-02-05
FIC20230036I1 (fi) 2023-12-01
IL302299A (en) 2023-06-01
BR112015031864B1 (pt) 2022-02-15
ES2773250T3 (es) 2020-07-10
AU2022202298A1 (en) 2022-04-28
FR23C1047I1 (fr) 2024-01-12
JP6980734B2 (ja) 2021-12-15
PH12015502794A1 (en) 2016-03-21
LT3010910T (lt) 2020-03-10
US20200297726A1 (en) 2020-09-24
PE20160208A1 (es) 2016-05-04
KR20160026997A (ko) 2016-03-09
DOP2015000300A (es) 2016-03-15
US9181200B2 (en) 2015-11-10
JP7376556B2 (ja) 2023-11-08
KR20220020410A (ko) 2022-02-18
EP3010910A1 (en) 2016-04-27
US20180311242A1 (en) 2018-11-01
CY1122964T1 (el) 2021-10-29
KR102359158B1 (ko) 2022-02-08
HUS2300042I1 (hu) 2024-01-28
AU2020204271A1 (en) 2020-07-16
MX2022014414A (es) 2022-12-07
IL317628A (en) 2025-02-01
MX2021005326A (es) 2022-11-17
LTC3010910I2 (pl) 2025-08-25
SMT202000071T1 (it) 2020-03-13
IL310829A (en) 2024-04-01
KR102304121B1 (ko) 2021-09-24
IL243222B (en) 2020-07-30
NL301253I1 (pl) 2023-12-13
HK1223930A1 (en) 2017-08-11
CY2023027I1 (el) 2024-02-16
AU2024202464A1 (en) 2024-05-02
PH12021552715A1 (en) 2022-05-11
WO2014205223A1 (en) 2014-12-24
UA117929C2 (uk) 2018-10-25
LTPA2023535I1 (pl) 2023-12-27
US20140378464A1 (en) 2014-12-25
GT201500348A (es) 2018-12-20
MY190860A (en) 2022-05-12
IL243222A0 (en) 2016-02-29
BR112015031864A2 (pt) 2017-07-25
EP3702352A1 (en) 2020-09-02
MX2015017865A (es) 2016-09-06
HUE047566T2 (hu) 2020-04-28
AU2014281408A1 (en) 2016-01-21
IL323967A (en) 2025-12-01
US20210346379A1 (en) 2021-11-11
CN105473576A (zh) 2016-04-06
CR20160032A (es) 2016-04-01
EA201891009A1 (ru) 2018-09-28
US20170281626A1 (en) 2017-10-05
US20240382486A1 (en) 2024-11-21
JP2022036966A (ja) 2022-03-08
JP6603213B2 (ja) 2019-11-06
AU2020204271B2 (en) 2022-01-06
CA2915967C (en) 2021-07-20
EA030846B1 (ru) 2018-10-31
IL275837B (en) 2021-09-30
JP2016522263A (ja) 2016-07-28
CN105473576B (zh) 2018-10-30
TN2015000553A1 (en) 2017-04-06
JP2020019809A (ja) 2020-02-06
USRE50050E1 (en) 2024-07-23
CN109384729A (zh) 2019-02-26
CY2023027I2 (el) 2024-09-20
IL285971A (en) 2021-10-31
JP2024010108A (ja) 2024-01-23
CA2915967A1 (en) 2014-12-24
SI3010910T1 (sl) 2020-04-30
SG11201510163TA (en) 2016-01-28
HRP20200379T1 (hr) 2020-06-12
ZA201508959B (en) 2022-09-28
US9585883B2 (en) 2017-03-07
PH12015502794B1 (en) 2022-09-02
PT3010910T (pt) 2020-02-21
CN109384729B (zh) 2023-06-30
AU2018264088A1 (en) 2018-12-06
EA201690066A1 (ru) 2016-05-31
NL301253I2 (nl) 2024-01-10
NZ715456A (en) 2021-01-29
SG10201803459TA (en) 2018-05-30
LUC00324I2 (pl) 2026-02-02
NO2023043I1 (no) 2023-12-01
JP2025163126A (ja) 2025-10-28
AU2014281408B2 (en) 2018-08-16
KR20230144117A (ko) 2023-10-13
DK3010910T3 (da) 2020-02-17
KR20210118470A (ko) 2021-09-30
US20160030428A1 (en) 2016-02-04
MX382520B (es) 2025-03-13
IL275837A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
CY2023027I2 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
EP2968894A4 (en) MEDICAL CONNECTOR
EP3821931C0 (en) ORONASAL PATIENT INTERFACE
DK2941163T3 (da) Hudrenser
EP2922514A4 (en) BI-RADIAL PATIENT INTERFACE
BR302014000263S1 (pt) Configuração aplicada em calçado
EP2968867C0 (en) CATHETER ASSEMBLY
FR3011445B1 (fr) Chaussure
PL2991633T3 (pl) Terapia bakteriofagami
FR3001392B1 (fr) Composition dermatologique amelioree
BR302014001196S1 (pt) Configuração aplicada em dispositivo médico
DK3089778T3 (da) Ballonkateter
BR302014001193S1 (pt) Configuração aplicada em dispositivo médico
BR302014001192S1 (pt) Configuração aplicada em dispositivo médico
BR302014001194S1 (pt) Configuração aplicada em dispositivo médico
DE112013006363A5 (de) Endoskop
FI20136034A7 (fi) Sauna
DE112014001827A5 (de) Gleitschuh
UA28338S (uk) Медичний пристрій-шприц
UA28339S (uk) Медичний пристрій-шприц
FI10036U1 (fi) Potilasalusta
ES1095431Y (es) "Sandalia"
EP2958932A4 (en) THERAPEUTICS
ES1093206Y (es) Construcción funeraria
BR302013006346S1 (pt) Configuração aplicada em sapato